Pavmed Inc. · NASDAQ:PAVM
Pavmed — IPO Roadshow (February 2016)
39 slides from Pavmed's IPO roadshow presentation, Feb 1, 2016
Slide 1: PAVmed Corporate Presentation February 2016
PAVmed INNOVATING AT THE SPEED OF LIFE TM CORPORATE PRESENTATION FEBRUARY 2016
Slide 2: Disclaimer
Disclaimer PAVMED INC. (“PAVMED”) HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS PAVMED HAS FILED WITH THE SEC FOR MORE
Slide 3: Company Overview
Company Overview
Slide 4: PAVmed Inc.
PAVmed Inc. PAVmed is an innovative multi-product medical device company, led by a team of entrepreneurs with a strong record of value creation, employing a proven capital and time efficient business model to advance an expanding pipeline of innovative products from concept to commercialization whil
Slide 5: Innovative multi-product medical device company
Innovative multi-product medical device company Unique, proven business model • Rapid speed to market • Highly capital efficient • High-margin, high-impact products addressing unmet clinical needs in attractive markets Leadership team with strong track record of value creation • Team created 4 succe
Slide 6: Leadership team with strong record of value creation
Leadership team with strong record of value creation LISHAN AKLOG, MD CHAIRMAN & CEO • A.B. Physics, magna cum laude • Phi Beta Kappa • M.D., cum laude • General Surgery Resident • Cardiothoracic Surgery Resident • Assistant Professor of Surgery • Associate Surgeon • Associate Chief of Cardiac Surge
Slide 7: Leadership team's prior track record of success
Leadership teamʼs prior track record of success COMPANY PRODUCT CAPITALIZATION COMMERCIALIZATION TIMELINE CURRENT STATUS ANGIOVAC™ Endovascular device to remove large clots and other undesirable intravascular material Mar 2008 $3.5M • Commercialized in Dec. 2009 • Acquired by Angiodynamics (Nasdaq:A
Slide 8: Proven record of delivering capital and time efficiency
Proven record of delivering capital and time efficiency TIME TO 510(K) CLEARANCE PAVmed Model Typical Company 0 12 24 36 48 60 Months CAPITAL TO 510(K) CLEARANCE PAVmed Model Typical Company $0 $10,000,000 $20,000,000 $30,000,000 Dollars *Typical Company data from Markower, et al. FDA Impact on US M
Slide 9: PAVmed builds on the leadership team's prior success
PAVmed builds on the leadership teamʼs prior success PAVmed INNOVATING AT THE SPEED OF LIFE TM The leadership team created PAVmed to leverage their proven business model in a long-term multi-product company with access to seamless capital through the public capital markets. PAVmedʼs structure enable
Slide 10: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE PortIO Long-term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors 12 Months Caldus Disposable Tissue Ablation Devices $2
Slide 11: Multi-product pipeline enhances value creation
Multi-product pipeline enhances value creation ECONOMIES OF SCALE “MULTIPLE SHOTS ON GOAL” NON-BINARY SUCCESS FLEXIBLE, DYNAMIC ALLOCATION OF RESOURCES ENHANCED VALUE CREATION
Slide 12: Board of Directors with industry and capital markets experience
Board of Directors with industry and capital markets experience LISHAN AKLOG, MD Chairman, Chief Executive Officer MICHAEL GLENNON Vice-Chairman RONALD M. SPARKS Director Nominating Committee Chair • Former Healthcare Industry Executive, Avista Capital Partners • Former Chairman and CEO, Navilyst, I
Slide 13: Multi-Specialty Medical Advisory Board of renowned physician innovators
Multi-Specialty Medical Advisory Board of renowned physician innovators ALBERT CHIN MD • Co-founding Partner and Chief Innovation Officer, Pavilion Medical Innovations • Former Vice President of Research and Chief Innovation Officer, Maquet Cardiovascular/ Guidant Cardiac Surgery • Inventor on 184 i
Slide 14: The PAVmed Business Model
The PAVmed Business Model
Slide 15: Project selection criteria drive commercial opportunity
Project selection criteria drive commercial opportunity TECHNOLOGY PROFILE REGULATORY PATHWAY UNMET CLINICAL NEED IN ATTRACTIVE MARKET COMMERCIAL OPPORTUNITY High-Margin High-Impact REIMBURSEMENT PROFILE
Slide 16: Key business processes deliver capital and time efficiency
Key business processes deliver capital and time efficiency PARALLEL DEVELOPMENT PROCESSES OUTSOURCED BEST-IN-CLASS PROCESS EXPERTS LIGHT INFRASTRUCTURE/ LOW FIXED COSTS CAPITAL AND TIME EFFICIENCY Maximize Value Creation RAPID COMMERCIALIZATION STRATEGY
Slide 17: Flexible commercialization strategy accelerates value creation
Flexible commercialization strategy accelerates value creation Initiate commercialization • Based on productʼs unique market profile • Rapid, iterative product development based on market feedback Accelerate revenue growth • Expand marketing and professional education • Leverage sales and marketing
Slide 18: Product Pipeline
Product Pipeline
Slide 19: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE PortIO Long-term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors 12 Months Caldus Disposable Tissue Ablation Devices $2
Slide 20: PAVmed's growing intellectual property portfolio
PAVmedʼs growing intellectual property portfolio PRODUCT INVENTORS TITLE NUMBER DATE PortIO Aklog, deGuzman and Orphanos “Intraosseous Infusion Ports and Methods of Use” Application# US62/0.79.266 US14940889 PCT/US15/60669 Filed 13-Nov-2014 13-Nov-2015 13-Nov-2015 Caldus Aklog and deGuzman “Continuo
Slide 21: PortIO
PortIO
Slide 22: Market Opportunity
Market Opportunity CLINICAL • Long-term implantable vascular access devices ADDRESSABLE MARKET • All implantable ports1 ~$500M • Poor venous access patients ~$50M CURRENT DEVICE LIMITATIONS • Intravascular component • Occlusions requiring intervention (30%2) • Device infections • Labor-intensive (re
Slide 23: PortIO - The PAVmed Solution
PortIO - The PAVmed Solution PORTIO • Novel, implantable intraosseous vascular access device • No intravascular component LESS INVASIVE • Near percutaneous insertion/removal MORE COST EFFECTIVE • Not prone to occlusions • No need for regular flushes • No radiographic confirmation necessary • Shift p
Slide 24: Caldus
Caldus
Slide 25: Market Opportunity
Market Opportunity CLINICAL • Ablation of pathologic soft tissues including tumors • Renal denervation for refractory hypertension ADDRESSABLE MARKET • Soft tissue ablation ~$200M/$100M1 Renal denervation ~$5B/$1B2 CURRENT DEVICE LIMITATIONS • Requires capital equipment (console) • Expensive • Requi
Slide 26: Caldus - The PAVmed Solution
Caldus - The PAVmed Solution CALDUS • Completely disposable tissue ablation devices • Direct thermal ablation • No console MORE COST EFFECTIVE • No capital and maintenance costs • Lower procedural cost while maintaining margin • Higher temperatures allow shorter ablation times EXPANDED MARKET • Lowe
Slide 27: CarpX
CarpX
Slide 28: Market Opportunity
Market Opportunity CLINICAL • Carpal tunnel syndrome (CTS) • Most common occupational injury ADDRESSABLE MARKET • ~2 million patients1 • 350,000 surgeries annually1 • All CTS patients $1.5B Current Surgical Patients $750M CURRENT DEVICE LIMITATIONS • Invasive surgical procedure • Endoscopic procedur
Slide 29: CarpX - The PAVmed Solution
CarpX - The PAVmed Solution CARPX • Completely percutaneous CTS device LESS INVASIVE • Truly percutaneous • No surgical incision or dissection MORE COST EFFECTIVE • Shift procedures interventional lab or office • Shorten procedural times FEWER COMPLICATIONS • Better nerve protection • Greater latera
Slide 30: NextCath
NextCath
Slide 31: Market Opportunity
Market Opportunity CLINICAL • Short-term catheters including peripheral venous catheters (PVC) ADDRESSABLE MARKET1 • 90% of inpatients receive a PVC • Short-term vascular catheters ~$2B Peripheral venous catheters ~$1B CURRENT DEVICE LIMITATIONS • Catheter dislodgement results in increased costs and
Slide 32: NextCath - The PAVmed Solution
NextCath - The PAVmed Solution NEXTCATH • Self-anchoring, short-term catheters • Integrated semi-stiff helical portion • Applicable to most, if not all, shortterm catheters MORE COST EFFECTIVE • Eliminate costly catheter securement devices • Less monitoring of catheter security • Fewer labor-intensi
Slide 33: NextFlo
NextFlo
Slide 34: Market Opportunity
Market Opportunity CLINICAL • Disposable infusion pumps (DIP) • Increasing numbers receiving infusions outside hospital ADDRESSABLE MARKET • DIPs for home use ~$500M CURRENT DEVICE LIMITATIONS • Highly inaccurate in actual use • Dependent on operating conditions • Unsuitable for use with many medica
Slide 35: NextFlo - The PAVmed Solution
NextFlo - The PAVmed Solution NEXTFLO • Highly accurate disposable infusion pump • Passive variable flow resistor design FEWER COMPLICATIONS • Prevent complications from infusions running too slow or fast MORE COST EFFECTIVE • Reduce or eliminate need for trained healthcare personnel • Decrease hosp
Slide 36: The Future of PAVmed
The Future of PAVmed
Slide 37: Expand pipeline in order to drive long-term growth
Expand pipeline in order to drive long-term growth Additional internal projects currently in conceptual phase • Extracorporeal circulation (ECMO) cannulas • Left atrial access for transcatheter mitral intervention • Endotracheal intubation • Sleep apnea • Laparoscopic hernia repair Company has been
Slide 38: Abundant near-and long-term opportunities for value creation
Abundant near-and long-term opportunities for value creation NEXT 12 MONTHS MILESTONES Complete lead product non-provisional patent applications PortIO FDA submission NextCath FDA submission NextFlo FDA submission PortIO FDA clearance and initial commercialization Caldus General FDA submission Caldu
Slide 39: PAVmed Investment Highlights
PAVmed Investment Highlights Unique, Proven Business Model Leadership Team with Strong Record of Value Creation Broad, Expanding Pipeline of Innovative Products World-Class Board and Advisors PAVmed INNOVATING AT THE SPEED OF LIFE TM